Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine-related cancer"
DOI: 10.1530/erc-20-0382
Abstract: Spartalizumab, a humanized anti-programmed death protein 1 (PD-1) monoclonal antibody, was evaluated in patients with well-differentiated metastatic grade 1/2 neuroendocrine tumors (NET) and poorly-differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC). In this phase II, multicenter, single-arm study,… read more here.
Keywords: gep nec; net group; nec group; spartalizumab metastatic ... See more keywords